scholarly journals An overview on seborrheic dermatitis and its treatment (allopathy and homeopathy)

2020 ◽  
Vol 7 (9) ◽  
pp. 1433
Author(s):  
Ch. Nagateja ◽  
G. Padmasree ◽  
B. Jaya Madhuri ◽  
K. Sailaja
Keyword(s):  
Seborrheic Dermatitis ◽  
Coal Tar ◽  
Newborn Infants ◽  
Calcineurin Inhibitors ◽  
Immunomodulatory Activity ◽  
Topical Steroids ◽  
Topical Calcineurin Inhibitors ◽  
Nasolabial Folds ◽  
Two Peaks ◽  
Selenium Sulfide

Seborrheic dermatitis is a common, chronic inflammation of the skin, characterized by the appearance of red, flaking, greasy areas of skin, most commonly on the scalp, nasolabial folds, ears, eyebrows and chest. The incidence of the disease has two peaks: one in newborn infants up to three months of age, and the other in adults of around 30-60years of age. The exact causes of seborrheic dermatitis are not completely understood, multiple factors appears to be involved in the pathophysiology of the disease. The principle three factors involved are: sebum secreted from sebaceous gland, presence of Malassezia yeast, and the immune response of the host. Currently allopathic treatment and prophylaxis regimens usually include antifungal agents, most often azoles, mild topical steroids, immunomodulatory activity of topical calcineurin inhibitors such as tacrolimus and pimecrolimus and other agents such as selenium sulfide, sulfur, metronidazole and coal tar. Homeopathy offers an excellent treatment for seborrheic dermatitis during all stages. Various homeopathic medicine used to treat seborrheic dermatitis are kali sulphuricum, thuja occidentalis, natrum muriaticum and more. The objective of this review is to discuss and provide information about seborrheic dermatitis and its epidemiology, etiology, pathogenesis, symptoms, diagnosis and its treatment in allopathy and homeopathy.

Off-Label Use of Topical Calcineurin Inhibitors in Dermatologic Disorders

2019 ◽  
Vol 23 (4_suppl) ◽  
pp. 27S-34S ◽  
Author(s):  
Lyn Guenther ◽  
Charles Lynde ◽  
Yves Poulin
Keyword(s):  
Lupus Erythematosus ◽  
Therapeutic Option ◽  
Seborrheic Dermatitis ◽  
Cutaneous Lupus Erythematosus ◽  
Calcineurin Inhibitors ◽  
Lichen Sclerosus ◽  
Hand Dermatitis ◽  
Off Label ◽  
Topical Calcineurin Inhibitors ◽  
Quality Evidence

Off-label prescribing is a common practice in dermatology, particularly when uncommon dermatologic diseases have limited or no approved treatment options. Topical calcineurin inhibitors are approved for the treatment of eczema, and their anti-inflammatory, immunomodulatory, and steroid-sparing effects make them an attractive therapeutic option for a wide variety of other dermatologic diseases. This review summarizes and qualifies the available evidence supporting the clinical effectiveness of tacrolimus ointment and pimecrolimus cream in non-eczema indications. There is high-quality evidence supporting the effectiveness of topical calcineurin inhibitors in multiple dermatological disorders including vitiligo; psoriasis of the face, folds, and genitals; seborrheic dermatitis; chronic hand dermatitis; contact dermatitis; oral lichen planus; lichen sclerosus; morphea; and cutaneous lupus erythematosus. Lower-quality evidence suggests they may be considered as an option in many other cutaneous disorders.

scholarly journals Lichen Planus Pigmentosus Inversus: A Rare Subvariant of Lichen Planus Pigmentosus

2021 ◽  
pp. 407-410
Author(s):  
Anne Guertler ◽  
Natalie Evenschor ◽  
Marlene Seegraeber ◽  
Lars Einar French ◽  
Véronique Weiler ◽  
...  
Keyword(s):  
High Risk ◽  
Lichen Planus ◽  
Medical Literature ◽  
Calcineurin Inhibitors ◽  
Skin Lesions ◽  
Topical Steroids ◽  
Skin Atrophy ◽  
Topical Calcineurin Inhibitors ◽  
Oral Corticosteroids ◽  
Safe Treatment Option

Lichen planus pigmentosus inversus (LPPI) is a rare subvariant of Lichen planus pigmentosus (LPP), presenting with sharply defined brown to gray macules, papules, and plaques limited to the intertriginous areas, with only a few cases reported in the medical literature so far. While LPP mostly affects patients with Fitzpatrick skin type III–IV in sun-exposed areas such as the neck, LPPI is seen in Caucasians and spares sun-exposed areas. Skin lesions tend to be very refractory to treatment attempts including potent topical steroids and oral corticosteroids. Given the increased penetration of potent topical steroids and the high risk of skin atrophy, especially when applied to intertriginous areas, this case shows that topical calcineurin inhibitors (tacrolimus 0.1%) might offer an effective and safe treatment option for LPPI.

scholarly journals Atopic dermatitis – Recent advances in the management

2021 ◽  
Vol 0 ◽  
pp. 1-5
Author(s):  
Ramkumar Ramamoorthy
Keyword(s):  
Atopic Dermatitis ◽  
Calcineurin Inhibitors ◽  
Skin Barrier ◽  
T Cell Subsets ◽  
Topical Steroids ◽  
Topical Calcineurin Inhibitors ◽  
Complex Interactions ◽  
Recent Advances ◽  
Molecular Events ◽  
Chronic Skin

Atopic dermatitis (AD) is a chronic skin disorder resulting from complex interactions between skin barrier defects and a dysregulated immune system, marked by activation of multiple T cell subsets at different stages of the disease. Until recently, the management of AD rested mainly on the judicious use of emollients, topical steroids, and topical calcineurin inhibitors in the majority of patients and systemic immunosuppressants were advocated in severely diseased. However, in the last few years, new therapeutic strategies were designed and developed to target the various steps in the chain of molecular events that lead to the AD phenotype. This review article will focus on the recent advances in the management of AD.

scholarly journals Epidemiology, Comorbidities, and Prescription Patterns of Korean Prurigo Nodularis Patients: A Multi-Institution Study

2021 ◽  
Vol 11 (1) ◽  
pp. 95
Author(s):  
Yu-Ri Woo ◽  
Sehee Wang ◽  
Kyung-Ah Sohn ◽  
Hei-Sung Kim
Keyword(s):  
Medical Center ◽  
Conditional Logistic Regression ◽  
Pearson Correlation ◽  
Calcineurin Inhibitors ◽  
Topical Steroids ◽  
Prurigo Nodularis ◽  
Prescription Patterns ◽  
Diagnostic Codes ◽  
Topical Calcineurin Inhibitors ◽  
Comorbidity Burden

Prurigo nodularis (PN) is a chronic dermatosis typified by extraordinarily itchy nodules. However, little is known of the nature and extent of PN in Asian people. This study aimed to describe the epidemiology, comorbidities, and prescription pattern of PN in Koreans based on a large dermatology outpatient cohort. Patients with PN were identified from the Catholic Medical Center (CMC) clinical data warehouse. Anonymized data on age, sex, diagnostic codes, prescriptions, visitation dates, and other relevant parameters were collected. Pearson correlation analysis was used to calculate the correlation between PN prevalence and patient age. Conditional logistic regression modeling was adopted to measure the comorbidity risk of PN. A total of 3591 patients with PN were identified at the Catholic Medical Center Health System dermatology outpatient clinic in the period 2007–2020. A comparison of the study patients with age- and sex-matched controls (dermatology outpatients without PN) indicated that PN was associated with various comorbidities including chronic kidney disease (adjusted odds ratio (aOR), 1.48; 95% confidence interval (CI), 1.29–1.70), dyslipidemia (aOR, 1.88; 95% CI, 1.56–2.27), type 2 diabetes mellitus (aOR, 1.37; 95% CI, 1.22–1.54), arterial hypertension (aOR, 1.50; 95% CI, 1.30–1.73), autoimmune thyroiditis (aOR, 2.43; 95% CI, 1.42–4.16), non-Hodgkin’s lymphoma (aOR, 1.95; 95% CI, 1.23–3.07), and atopic dermatitis (aOR, 2.16, 95% CI, 1.91–2.45). Regarding prescription patterns, topical steroids were most favored, followed by topical calcineurin inhibitors; oral antihistamines were the most preferred systemic agent for PN. PN is a relatively rare but significant disease among Korean dermatology outpatients with a high comorbidity burden compared to dermatology outpatients without PN. There is great need for breakthroughs in PN treatment.

Comorbidity and Therapeutic Approaches in Patients with Necrobiosis Lipoidica

Dermatology ◽  
2021 ◽  
pp. 1-8
Author(s):  
Cornelia Erfurt-Berge ◽  
Veronika Heusinger ◽  
Finja Reinboldt-Jockenhöfer ◽  
Joachim Dissemond ◽  
Regina Renner
Keyword(s):  
Fumaric Acid ◽  
Calcineurin Inhibitors ◽  
Compression Therapy ◽  
Topical Steroids ◽  
Necrobiosis Lipoidica ◽  
Therapeutic Approaches ◽  
Fumaric Acid Esters ◽  
Topical Calcineurin Inhibitors ◽  
Randomized Controlled Studies ◽  
Acid Esters

<b><i>Background:</i></b> Necrobiosis lipoidica (NL) is a rare granulomatous disorder of unknown aetiology. Randomized controlled studies are not available due to it being an orphan disease. <b><i>Objectives:</i></b> We evaluated patients in 2 dermatological centres to cluster data about epidemiology, the therapeutic approaches for NL, and their efficacy. <b><i>Materials and Methods:</i></b> Comorbidity and the efficacy of the applied treatment was assessed for 98 patients. <b><i>Results:</i></b> We identified 54% of patients with concomitant diabetes and 19% with thyroidal disorders. Topical steroids (85.7%) were predominantly used followed by calcineurin inhibitors (31%) and phototherapy (41.8%). Systemically, fumaric acid esters were more frequently applied (26.8%) than steroids (24.4%) and dapsone (24.4%). Steroids, compression therapy, calcineurin inhibitors, phototherapy, fumaric acid esters, and dapsone showed remarkable efficacy. <b><i>Conclusion:</i></b> Therapeutic options were chosen individually in accordance with the severity of NL and presence of ulceration. Topical calcineurin inhibitors, systemic application of fumaric acid esters, and dapsone represent effective alternatives to the use of steroids.

Topical Treatment of Mild to Moderate Psoriasis

2010 ◽  
Vol 16a (2) ◽  
pp. 17-25
Author(s):  
Daniel Gold ◽  
Saad I. Almohizea
Keyword(s):  
Vitamin D ◽  
Salicylic Acid ◽  
Topical Treatment ◽  
Coal Tar ◽  
Calcineurin Inhibitors ◽  
Vitamin D Analogs ◽  
Topical Calcineurin Inhibitors ◽  
Systemic Therapies

Topical therapies are used by most psoriasis patients either alone or in combination with systemic therapies and phototherapy. The objective of this paper is to review the different topical therapies to treat mild to moderate psoriasis, including corticosteroids, vitamin D analogs, tazarotene, topical calcineurin inhibitors, anthralin, salicylic acid, and coal tar and assess their effectiveness and tolerability. Topical therapies are important for treating psoriasis and will continue to play a major role even as new systemic therapies emerge.

Therapy-related issues: skin

2017 ◽  
Author(s):  
Philip Wiffen ◽  
Marc Mitchell ◽  
Melanie Snelling ◽  
Nicola Stoner
Keyword(s):  
Wound Care ◽  
Coal Tar ◽  
Calcineurin Inhibitors ◽  
Wound Dressings ◽  
Topical Calcineurin Inhibitors ◽  
Topical Antimicrobials ◽  
Skin Conditions ◽  
Selection Of

This chapter outlines information relevant to pharmacists and other healthcare professionals related to selected skin conditions. The review of wound care includes classification of wounds, selection of wound dressings, and a discussion of other wound care products and practices including topical antimicrobials, honey, larval therapy, and vacuum-assisted closure. Management of eczema covers the use of emollients, corticosteroids, and topical calcineurin inhibitors. The different treatments available to treat psoriasis are discussed, ranging from older agents such as coal tar to the role of biologics.

Sign in / Sign up

Export Citation Format

Share Document